Raphe mPhibr is one of the most important private defence-tech companies to emerge from India’s drone ecosystem in the last decade. The Noida-based company has built a portfolio spanning surveillance drones, high-altitude logistics UAVs, swarm systems, maritime platforms, autonomous navigation, ground-control systems, carbon-fibre structures, electronics and propulsion. It has also attracted unusually large private capital for an Indian defence start-up, including a $100 million funding round led by General Catalyst in June 2025, taking total disclosed funding to about $145 million. The Economic Times reported that the round valued the company at nearly $900 million. General Catalyst Economic Times
The story, however, is more complicated than a simple “Indian drone unicorn” narrative. Raphe has real products, real defence customers, deep manufacturing ambition and a large order pipeline. At the same time, its latest available credit-rating data show a sharp slowdown in order execution during FY26, substantial operating losses in the first nine months of the year, high working-capital requirements and heavy dependence on imported raw materials. That combination makes Raphe one of the most interesting defence companies in India to study precisely because the opportunity and the execution risk are both unusually large. CARE Ratings
For readers looking at Raphe specifically from an investor-access angle, including its known shareholders, private funding rounds, unlisted-share routes, reported valuation and possible IPO path, read our companion analysis: Raphe mPhibr Share Price, Shareholders & IPO: How Can You Invest?.
From Research Project to Defence Manufacturer
Raphe mPhibr was incorporated in 2017 and was founded by technologists Vikash Mishra, Vivek Mishra and Nitin Katiyar. Vikash Mishra, now Chairman, has a background in mechanical and aerospace research, while Vivek Mishra, the CEO, focuses on electronics, controls, robotics and artificial intelligence. Nitin Katiyar heads the software side of the business. CARE Ratings describes the three founders as the core technical leadership behind the company’s UAV systems. CARE Ratings
The founders’ approach was unusually research-heavy from the beginning. In interviews, the company has said that it spent its early years understanding military operating conditions before scaling products. Raphe started from a research facility of only about 2,000 square feet and later expanded into a much larger integrated R&D and manufacturing operation in Noida. By 2025, the company had expanded to a campus of roughly 650,000 square feet, according to TechCrunch. Its current careers page says the organisation has grown to 800+ team members across more than 30 disciplines. TechCrunch Raphe mPhibr
That scale matters because Raphe is not positioning itself as a company that simply assembles imported drone kits. Its stated strategy is vertical integration: design the aircraft, build the electronics, manufacture composite structures, develop software, make propulsion systems and control the testing process internally. The company’s own website lists additive manufacturing, PCB assembly, subtractive manufacturing and composite manufacturing among its internal capabilities. Raphe mPhibr
What Raphe Actually Builds
Raphe’s public product portfolio covers several different military roles. The mR20 is designed for high-altitude logistics and resupply. The mR10 family is a multi-role platform that includes swarm applications. The Bharat drone is a lightweight, man-portable surveillance platform intended for fast deployment in difficult terrain. The X8 is aimed at maritime patrol and situational awareness. Raphe has also developed fixed-wing and VTOL aircraft, including the Neeraj platform. Janes TechCrunch
The company’s technology page claims aircraft capability of up to 100 kg payload, up to 360 minutes of flight time and surveillance range of up to 150 km, depending on platform. It also says its swarm architecture can coordinate up to 100 UAVs with AI-enabled automatic detection and tracking. Those figures are company-reported specifications and should be read as platform capability claims rather than uniform specifications across every Raphe product. Raphe mPhibr
What makes Raphe particularly interesting is that the company is trying to own more of the UAV technology stack than many early-stage drone makers. Its disclosed technology work includes ultra-light carbon-fibre composites, simultaneous localisation and mapping for autonomous navigation, ground-control systems, aerodynamics simulation, multi-layer PCB design, software, electronics integration and a domestically developed two-stroke engine that uses metal additive manufacturing. Raphe mPhibr
This vertical-integration strategy can be expensive, but it can also reduce dependence on external suppliers over time and make it easier to customise products for specific military missions. That is especially relevant in defence procurement, where the customer may need a platform redesigned around terrain, payload, communication range, endurance or electronic-warfare conditions rather than buying a standard commercial drone.
The Indian Armed Forces Are Already Customers
Raphe is not a pre-revenue technology experiment. TechCrunch reported in 2025 that the company had more than 10 government customers, including the Indian Army, Indian Navy, Indian Air Force, Border Security Force, Central Reserve Police Force and Indo-Tibetan Border Police. The same report said Raphe had sold more than 300 drones in the preceding 12 months. TechCrunch
The company has also received meaningful military contracts over several years. A 2023 DRDO media compilation noted that the Army had placed orders for 48 mR20 logistics drones and 100 quadcopters from Raphe. Earlier reporting also linked the company to one of the Indian Army’s first drone-swarm procurements. DRDO India Today
More recently, a Ministry of Defence procurement for seven high-end hexacopter drones in 2026 was awarded to Raphe through the Government e-Marketplace process, according to a tender-data platform tracking the GeM result. The disclosed tender value was around ₹10 crore. BidEasy / GeM tender data
Raphe was also one of the drone manufacturers shortlisted under India’s drone Production Linked Incentive programme. The Ministry of Civil Aviation published Raphe among the shortlisted manufacturers in 2022. PIB
Operation Sindoor Gave Raphe an Important Validation Point
One of the strongest public validations of Raphe’s technology came from the Ministry of Defence in August 2025. At the inauguration of the company’s new test facility in Noida, Defence Minister Rajnath Singh said that three products developed jointly by Raphe mPhibr and DRDO within 14 months were deployed during Operation Sindoor. PIB
The government release did not publicly identify all three systems in detail, so it would be wrong to speculate about their exact operational role. What can be stated with confidence is that the Ministry of Defence publicly acknowledged Raphe-DRDO systems as having been deployed during the operation.
That matters commercially because defence start-ups often face a long gap between prototype development and operational acceptance. A platform that has gone through military deployment, testing and user feedback can have a stronger position in future procurement than a product that exists only at demonstration stage.
Raphe Is Building More Than a Drone Factory
The Noida expansion shows that Raphe’s ambitions extend beyond assembling UAV airframes. In August 2025, the company inaugurated a new defence equipment and test facility that included an engine test bed, metal additive-manufacturing capability, high-temperature furnaces and composite-polymer manufacturing infrastructure. Government-linked reporting described the facility as including one of the country’s largest aero-engine test beds. PIB ETGovernment
The logic is clear. If Raphe can manufacture more propulsion, electronics, structures and test systems internally, it can move from being simply a drone vendor toward becoming a broader aircraft and defence-systems company.
That is also consistent with the wording used by General Catalyst when it invested. The investor described Raphe not merely as a drone start-up but as a next-generation Indian defence and aircraft-manufacturing company with ambitions to build a vertically integrated defence platform. General Catalyst
Partnerships Add Foreign Technology Without Making Raphe a Simple Importer
Raphe has also built relationships with established European aerospace and defence companies.
At Aero India 2025, Germany’s HENSOLDT signed an agreement with Raphe to co-develop a MIMO-based landing-aid radar for next-generation aviation platforms. The partnership also covers localised production of advanced sensor payloads in India. New Indian Express
TechCrunch also reported collaboration with Safran on sensors and with Dassault Systèmes for design and simulation software. Raphe says Dassault’s 3DEXPERIENCE platform is being used to accelerate simulation, validation and UAV development. TechCrunch Raphe mPhibr
These partnerships fit a more sophisticated model than simple foreign technology transfer. Raphe appears to be using external sensor and software expertise around an internally developed aircraft, electronics and manufacturing stack.
Funding Has Become a Strategic Advantage
Raphe’s capital base is unusual for an Indian defence start-up.
The company announced a $100 million equity round in June 2025, led by General Catalyst with participation from Think Investments, Amal Parikh and other investors. The company said the transaction took total capital raised to $145 million. Raphe mPhibr
CARE Ratings provides another useful view of that capital raising. It says Raphe raised ₹459 crore of equity in FY25 and another ₹485 crore through compulsory convertible preference shares during FY26. These funds were used largely for capital expenditure, R&D and working capital. CARE Ratings
The Economic Times reported that the 2025 transaction valued Raphe at close to $900 million, although CEO Vivek Mishra did not publicly confirm the number in a separate Moneycontrol interview. Economic Times Moneycontrol
For a company in defence manufacturing, this kind of patient private capital matters because product development can take years before a large procurement turns into revenue. It also gives Raphe the ability to invest in equipment, engineers and inventory before orders are fully delivered.
But the same funding story should not hide the fact that the company still has to prove consistent order execution.
FY25 Looked Like a Breakout Year
The financial trajectory through FY25 was impressive on the top line.
According to CARE Ratings, Raphe’s total operating income rose from ₹85.19 crore in FY24 to ₹263.84 crore in FY25, more than tripling in one year. PBILDT increased from ₹19.86 crore to ₹35.40 crore. CARE Ratings
However, profitability did not scale with revenue. Raphe’s PBILDT margin fell from 22.49% in FY24 to 12.64% in FY25, and PAT declined from ₹8.95 crore to ₹6.50 crore despite the sharp rise in revenue.
CARE attributed part of the margin pressure to lower sales booked in the fourth quarter and higher fixed overheads, particularly employee costs. An approximately ₹83 crore Indian Army order expected to be delivered by March 2025 was delayed.
That is an important clue to how Raphe’s business behaves. Revenue is not smooth like a consumer company or subscription-software business. Large defence platforms require design, validation, customer inspection and scheduled delivery. One delayed programme can move a large amount of revenue from one financial period into another.
FY26 Exposed the Execution Risk
The biggest weakness in the current Raphe story is visible in the first nine months of FY26.
CARE Ratings reported that total operating income fell to only ₹12.67 crore in 9MFY26. Raphe recorded a PBILDT loss of ₹158.29 crore and a PAT loss of ₹183.60 crore during the period. CARE consequently downgraded its bank-facility rating from CARE BBB- to CARE BB+ with a Stable outlook in April 2026. CARE Ratings
This is a major deterioration and should not be buried beneath the funding headline.
CARE said the loss was caused mainly by orders not progressing to execution on the expected schedule while Raphe continued carrying high fixed costs, particularly employee expenses.
In other words, the company had built the organisation and production base for a much larger revenue run-rate, but customer-order conversion slipped. That creates severe operating leverage in reverse: when deliveries are delayed, the cost base remains but revenue disappears.
The Order Book Is Also the Strongest Part of the Story
The surprising part is that CARE did not describe Raphe as having weak demand.
Quite the opposite.
As of March 23, 2026, CARE said Raphe had an unexecuted order book equal to about 22 times FY25 total operating income. Most of those orders were from government customers including the Indian Army and Indian Navy, with some orders from private clients. CARE Ratings
That is an enormous order-book-to-revenue ratio.
It means the central question around Raphe is not simply, “Can the company win orders?”
It is, “How quickly can Raphe convert those orders into tested, accepted and delivered systems?”
CARE notes that projects based on existing designs can be completed in less than a year, while programmes requiring customisation can take longer because of extensive R&D.
This is the single most important metric to watch going forward. If the backlog converts successfully, Raphe’s revenue base can change dramatically. If execution remains slow, the order book can stay impressive on paper while losses and working-capital requirements continue.
Working Capital Is a Structural Challenge
Raphe’s operating cycle improved materially in FY25, but it remained long.
CARE reported an operating cycle of 191 days in FY25, down from 489 days in FY24. Inventory alone represented 166 days.
That is not entirely surprising for defence manufacturing. Raphe may procure components, engineer a platform, customise it, test it and then wait for pre-delivery inspection before final acceptance.
But the financial consequence is significant: cash can remain tied up in inventory for months before revenue and collection occur. This is the same reason investors should never stop at headline revenue and PAT; Credivant’s guide on testing reported growth against cash flow, receivables and inventory explains why cash conversion matters, while our trade-receivable ageing guide shows how delayed collections can change the quality of reported sales.
CARE also expected inventory to remain elevated because Raphe had procured material in advance for orders scheduled to be executed in FY27. CARE Ratings
The “Indigenous” Story Still Has an Import Dependence
Raphe emphasises indigenous design and manufacturing, but one financial detail deserves attention.
CARE says approximately 80–85% of raw materials are imported, including materials or components such as carbon fibre, motors, battery cells and camera lenses. Imports come from countries including the UK, Germany, Switzerland and France. Raphe did not have a foreign-exchange hedging policy for this exposure at the time of the rating review. CARE Ratings
This does not contradict the fact that Raphe designs and manufactures substantial parts of its systems in India. Defence platforms can be domestically designed while still using imported subsystems or materials.
But it shows that complete supply-chain independence has not yet been achieved.
For investors analysing the defence-indigenisation theme, that distinction is important. The long-term opportunity is not only to assemble more in India, but to progressively localise critical materials, sensors, propulsion, batteries and electronics.
Debt Is Manageable Because Equity Funding Has Been Large
CARE rated ₹643 crore of bank facilities in April 2026, including ₹543 crore of long-term facilities and ₹100 crore of combined long-term/short-term facilities.
Despite FY26 losses, the company’s overall gearing was 0.48x as of December 31, 2025, largely because of the large equity and preference-capital infusions. CARE described Raphe’s financial risk profile as comfortable from a leverage perspective, even while classifying liquidity as stretched because current operations were loss-making. CARE Ratings
Raphe had around ₹15 crore of free cash and bank balances as of March 23, 2026, according to CARE.
This is why the General Catalyst-led fundraise is more than a valuation milestone. It is effectively financing the gap between heavy upfront R&D/manufacturing investment and the delayed recognition of defence revenue.
Raphe’s Biggest Strategic Moat Could Be Vertical Integration
Most of the company’s strongest long-term arguments come back to the same idea: Raphe is trying to control a very large part of the technology chain.
A defence drone is not just an airframe. It depends on composites, propulsion, flight computers, navigation, communications, payloads, autonomous software, ground control and manufacturing quality.
Raphe is attempting to build capability across many of those layers.
That gives the company more engineering control, but it also creates a very high fixed-cost base. Scientists, electronics engineers, aerospace researchers, software teams, composite manufacturing, testing infrastructure and advanced machine tools all need to be funded before a delivery is accepted.
That is both the moat and the risk.
If scale arrives, the fixed infrastructure becomes powerful.
If order conversion remains slow, the same infrastructure becomes expensive.
International Expansion Is Still More Ambition Than Reported Revenue
Raphe has publicly signalled that exports are an important next step.
In 2025, CEO Vivek Mishra told TechCrunch that the company already had some export licences and was in advanced discussions with government agencies outside India. Raphe has also displayed systems at international defence exhibitions in Paris and Dubai. TechCrunch
However, publicly available information does not yet establish a large export revenue base comparable with the company’s domestic defence business.
That means investors should treat exports as a future growth option rather than assume global military sales are already meaningful.
Could Raphe mPhibr Eventually Come to the Stock Market?
Raphe remains an unlisted private company as of September 2026.
In the 2025 TechCrunch interview, Vivek Mishra said the company could potentially go public within two to five years. That was management commentary, not a formal IPO filing. TechCrunch
No public DRHP for Raphe mPhibr was found in our review as of September 27, 2026.
If Raphe eventually files for an IPO, the prospectus will be particularly interesting because public investors will finally get much deeper visibility into product-level revenue, customer concentration, order execution, cash flow, R&D spending, imported components and the ownership structure after multiple private funding rounds. At that stage, investors can use Credivant’s IPO RHP red-flag checklist to examine the offer document, and our Fresh Issue vs OFS explainer to understand whether IPO proceeds go into Raphe itself or to selling shareholders.
The Investment Case — If It Ever Becomes Public
Raphe has several qualities public-market investors usually look for in an emerging defence platform: a strategic sector, large government customers, operational products, growing manufacturing capability, deep R&D, a sizeable order book and strong institutional backing.
It also carries risks that public investors should take equally seriously: highly lumpy revenue, dependence on government procurement schedules, long design and acceptance cycles, imported raw materials, technology-obsolescence risk, a working-capital-heavy model and the possibility that a large order book converts much more slowly than expected.
The FY25–FY26 contrast captures the entire story.
FY25 showed what Raphe can look like when deliveries move.
9MFY26 showed what happens when they do not.
That is why the company cannot be understood from valuation, funding or defence-sector excitement alone.
The Bigger Picture
Raphe mPhibr is important because it represents a new type of Indian industrial company.
It is not a software start-up that happens to sell to defence customers, and it is not a traditional public-sector defence manufacturer. It is trying to build a privately funded, research-led, vertically integrated aerospace company capable of designing platforms from the material level upward.
That ambition explains why investors such as General Catalyst are willing to commit large amounts of capital before the financial statements look smooth.
But ambition and technical sophistication eventually have to produce repeatable execution.
Raphe has already shown that it can build technology, win military customers, raise capital and secure a very large order backlog. The next phase is harder: converting that backlog into revenue and cash at a pace that supports the manufacturing and research organisation it has already created.
If it succeeds, Raphe could become one of the most consequential private aerospace manufacturers to come out of India.
If execution remains inconsistent, the same scale of investment that makes the company exciting could also keep financial volatility high.
For now, Raphe mPhibr is best understood not as a simple “drone start-up,” but as an ambitious defence-aerospace manufacturing platform in the middle of a difficult transition from engineering capability to industrial-scale execution.
If your main question is whether ordinary investors can buy Raphe today, who its known investors are and what the realistic pre-IPO routes look like, read the separate Credivant guide: Raphe mPhibr Share Price, Shareholders & IPO: How Can You Invest?.
Disclaimer: Raphe mPhibr is an unlisted private company. This article is an independent research analysis based on publicly available company disclosures, government releases, credit-rating reports and media reporting. It is not an investment recommendation. Operational specifications quoted from Raphe’s website are company-reported figures and may vary by platform and mission configuration.